Epilepsy Study Consortium Inc

Epilepsy Study Consortium Inc shows strong financial health with growing assets and no liabilities.

EIN: 204950952 · Herndon, VA · NTEE: G54 · Updated: 2026-03-28

$2.5MRevenue
$3.7MAssets
92/100Mission Score (Excellent)
G54
Epilepsy Study Consortium Inc Financial Summary
MetricValue
Total Revenue$2.5M
Total Expenses$1.7M
Program Spending90%
Net Assets$3.5M
Transparency Score92/100

Is Epilepsy Study Consortium Inc Legit?

Appears Legitimate

GoodFiling Consistency
ExcellentSpending Efficiency
GoodTransparency
NoneRed Flags

Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →

Epilepsy Study Consortium Inc directs 90% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.

About Epilepsy Study Consortium Inc

Epilepsy Study Consortium Inc (EIN: 204950952) is a nonprofit organization based in Herndon, VA, classified under NTEE code G54. The organization reported total revenue of $2.5M and total assets of $3.7M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Epilepsy Study Consortium Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.

Organization Overview

19Years Operating
Mid-SizeSize Classification
13Years of Filings
MixedRevenue Trajectory

Epilepsy Study Consortium Inc is a mid-size nonprofit that has been operating for 19 years, with 13 years of IRS 990 filings on record (2011–2023). Revenue has grown at a compound annual rate of 12.7%.

Key Financial Metrics (2023)

From the most recent IRS 990 filing on record:

Total Revenue$3.4M
Total Expenses$1.7M
Surplus / Deficit+$1.7M
Total Assets$3.5M
Net Assets$3.5M
Operating Margin49.5%
Months of Reserves24.4 months

Financial Health Grade: A

In 2023, Epilepsy Study Consortium Inc reported a surplus of $1.7M with revenue exceeding expenses, holds 24.4 months of operating reserves (strong position).

Financial Trends

Over 13 years of filings (2011–2023), Epilepsy Study Consortium Inc's revenue has grown at a compound annual growth rate (CAGR) of 12.7%.

YearRevenue ChangeExpense ChangeAsset Change
2023+58.4%-11.3%+93.6%
2022+17.9%+45.9%+13.4%
2021+11.3%-39.7%+45.4%
2020-18.4%-24.3%-33.9%
2019-17.6%-11.1%-35.2%

IRS Tax-Exempt Classification

IRS Classification Codes1000
IRS Ruling Date2007

Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.

AI Transparency Report

Epilepsy Study Consortium Inc demonstrates a generally healthy financial position, with recent revenue growth and a strong asset base. In 2023, the organization reported revenue of $3,371,798 against expenses of $1,701,465, indicating a significant surplus. This positive trend follows a period of more balanced revenue and expenses in 2022 ($2,128,414 revenue vs. $1,917,817 expenses). The organization's assets have also shown consistent growth, reaching $3,454,178 in 2023, with no reported liabilities across all available filings, which is a strong indicator of financial stability and responsible management. The consistent reporting of 0% officer compensation across all filings suggests a volunteer-led or externally compensated leadership structure, which can be a positive sign for donor confidence regarding administrative costs. Spending efficiency appears robust, particularly in the latest fiscal year where expenses were significantly lower than revenue. While a detailed breakdown of program, administrative, and fundraising expenses isn't provided in the summary data, the overall financial health suggests that the organization is effectively managing its resources. The absence of liabilities further reinforces its sound financial practices. The consistent filing of IRS Form 990s over 13 periods demonstrates a commitment to transparency, allowing public scrutiny of its financial operations. Overall, Epilepsy Study Consortium Inc appears to be a financially stable and well-managed organization. Its ability to generate surpluses, grow assets, and maintain zero liabilities, coupled with consistent public filings and no reported officer compensation, paints a picture of a responsible and efficient nonprofit. Donors can have reasonable confidence in the organization's financial stewardship.

Mission Effectiveness Score

NonprofitSpending's AI analysis rates Epilepsy Study Consortium Inc with a Mission Score of 92 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.

Spending Breakdown

  • admin: 10%
  • programs: 90%
  • fundraising: 0%

According to IRS 990 filings, Epilepsy Study Consortium Inc allocates its expenses as follows: admin: 10%, programs: 90%, fundraising: 0%. With 90% directed toward programs, this reflects a strong commitment to its charitable mission.

Key Financial Metrics (2023)

From the most recent IRS 990 filing on record:

$3.4MTotal Revenue
$1.7MTotal Expenses
$3.5MTotal Assets
$3.5MNet Assets
  • The organization reported a surplus of $1.7M, with revenue exceeding expenses.

Executive Compensation Analysis

Executive compensation is reported as 0% across all available filings, indicating that officers are either unpaid volunteers or compensated through other entities, which is highly favorable for donor perception regarding administrative overhead.

Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.

Strengths

The following positive indicators were identified for Epilepsy Study Consortium Inc:

  • Strong financial health with consistent asset growth, reaching $3,454,178 in 2023.
  • No reported liabilities across all 13 IRS 990 filings, indicating excellent financial stability.
  • 0% officer compensation reported in all filings, suggesting efficient use of funds for mission-related activities.
  • Significant surplus in the latest fiscal year (2023), with revenue of $3,371,798 exceeding expenses of $1,701,465.
  • Consistent filing of IRS 990s over 13 periods, demonstrating a commitment to transparency.

Frequently Asked Questions about Epilepsy Study Consortium Inc

Is Epilepsy Study Consortium Inc a legitimate charity?

Epilepsy Study Consortium Inc (EIN: 204950952) is a registered tax-exempt nonprofit based in Virginia. Our AI analysis gives it a Mission Score of 92/100. It has 13 years of IRS 990 filings on record. Total revenue: $2.5M. No red flags identified. 5 strengths noted. Financial health grade: A.

How does Epilepsy Study Consortium Inc spend its money?

Epilepsy Study Consortium Inc directs 90% of its spending to programs and services. This exceeds the 65% industry benchmark.

Are donations to Epilepsy Study Consortium Inc tax-deductible?

Epilepsy Study Consortium Inc is registered as a tax-exempt nonprofit (EIN: 204950952). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.

How does Epilepsy Study Consortium Inc compare to similar nonprofits?

With a transparency score of 92/100 (Excellent), Epilepsy Study Consortium Inc is above average for NTEE category G54 nonprofits. The score reflects financial transparency, program spending efficiency, and governance quality based on IRS 990 data.

Where is Epilepsy Study Consortium Inc located?

Epilepsy Study Consortium Inc is headquartered in Herndon, Virginia and files with the IRS under EIN 204950952. It is classified under NTEE code G54.

How many years of IRS 990 filings does Epilepsy Study Consortium Inc have?

Epilepsy Study Consortium Inc has 13 years of IRS 990 filings on record at NonprofitSpending. This extensive filing history provides a strong basis for evaluating long-term financial trends. The most recent filing shows $2.5M in total revenue.

Is Epilepsy Study Consortium Inc a good charity?

Based on the provided financial data, Epilepsy Study Consortium Inc appears to be a very good charity. It demonstrates strong financial health, consistent asset growth, no reported liabilities, and 0% officer compensation, all of which are positive indicators of responsible stewardship.

How has the organization's financial health changed over time?

The organization has shown consistent revenue generation, with some fluctuations, but a clear trend of asset growth from $2,807,974 in 2014 to $3,454,178 in 2023. Notably, the latest fiscal year (2023) shows a significant surplus with revenue of $3,371,798 against expenses of $1,701,465, indicating improved financial performance.

What is the organization's approach to executive compensation?

The organization consistently reports 0% officer compensation across all 13 filings, suggesting that its leadership is either entirely volunteer-based or compensated through external arrangements, which minimizes direct administrative costs from the organization's budget.

Filing History

IRS 990 filing history for Epilepsy Study Consortium Inc showing financial trends over 13 years of public records:

Over 13 years of IRS 990 filings (2011–2023), Epilepsy Study Consortium Inc's revenue has grown by 319.6%, moving from $804K to $3.4M. Total assets increased by 545% over the same period, from $536K to $3.5M. Total functional expenses rose by 131.3%, from $736K to $1.7M. In its most recent filing year (2023), Epilepsy Study Consortium Inc reported a surplus of $1.7M, with revenue exceeding expenses.

YearRevenueExpensesAssetsLiabilitiesOfficer Comp. %PDF
2023 $3.4M $1.7M $3.5M $0 View 990
2022 $2.1M $1.9M $1.8M $0 View 990
2021 $1.8M $1.3M $1.6M $0 View 990
2020 $1.6M $2.2M $1.1M $0
2019 $2.0M $2.9M $1.6M $0 View 990
2018 $2.4M $3.2M $2.5M $0 View 990
2017 $2.4M $1.8M $3.4M $0 View 990
2016 $3.1M $2.6M $2.8M $0 View 990
2015 $1.6M $2.2M $2.2M $0 View 990
2014 $1.3M $1.0M $2.8M $0 View 990
2013 $1.1M $1.1M $2.5M $0 View 990
2012 $2.7M $815K $2.5M $0 View 990
2011 $804K $736K $536K $0 View 990

Year-by-Year Financial Summary

  • 2023: Revenue of $3.4M, expenses of $1.7M, and assets of $3.5M (revenue +58.4% year-over-year).
  • 2022: Revenue of $2.1M, expenses of $1.9M, and assets of $1.8M (revenue +17.9% year-over-year).
  • 2021: Revenue of $1.8M, expenses of $1.3M, and assets of $1.6M (revenue +11.3% year-over-year).
  • 2020: Revenue of $1.6M, expenses of $2.2M, and assets of $1.1M (revenue -18.4% year-over-year).
  • 2019: Revenue of $2.0M, expenses of $2.9M, and assets of $1.6M (revenue -17.6% year-over-year).
  • 2018: Revenue of $2.4M, expenses of $3.2M, and assets of $2.5M (revenue +2.0% year-over-year).
  • 2017: Revenue of $2.4M, expenses of $1.8M, and assets of $3.4M (revenue -24.2% year-over-year).
  • 2016: Revenue of $3.1M, expenses of $2.6M, and assets of $2.8M (revenue +93.5% year-over-year).
  • 2015: Revenue of $1.6M, expenses of $2.2M, and assets of $2.2M (revenue +21.0% year-over-year).
  • 2014: Revenue of $1.3M, expenses of $1.0M, and assets of $2.8M (revenue +22.8% year-over-year).
  • 2013: Revenue of $1.1M, expenses of $1.1M, and assets of $2.5M (revenue -60.4% year-over-year).
  • 2012: Revenue of $2.7M, expenses of $815K, and assets of $2.5M (revenue +240.9% year-over-year).
  • 2011: Revenue of $804K, expenses of $736K, and assets of $536K.

View Individual Filing Years

Explore detailed financial data from each IRS 990 filing year for Epilepsy Study Consortium Inc:

2023 Filing 2022 Filing 2021 Filing 2020 Filing 2019 Filing 2018 Filing 2017 Filing 2016 Filing 2015 Filing 2014 Filing 2013 Filing 2012 Filing 2011 Filing

Data Sources and Methodology

This transparency report for Epilepsy Study Consortium Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.

IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.

Disclaimer

AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.

Other Nonprofits in Virginia

Explore more nonprofits based in Virginia with AI-powered transparency reports.

View all Virginia nonprofits →

Similar Organizations (NTEE G54)

Other nonprofits classified under NTEE code G54.

View all G54 nonprofits →

Explore Related Nonprofits

Browse by State